(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Giulia Baciarello discussing results from the phase 2 CABA-GCT trial. Men with advanced germ cell tumors with cancer progression after 2-3 lines of chemotherapy have a poor prognosis with currently no standard treatment. Taxanes have established activity in germ cell tumor. Cabazitaxel may cross the blood-brain barrier (the brain is a frequent site of progression in highly pretreated patients) and has limited peripheral neuro-toxicity, two major potential advantages for these patients. At the 2021 ESMO congress, Dr. Baciarello and colleagues presented results of this phase 2 trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors.